Compare DexCom, Inc. (DXCM) vs Standard Lithium Ltd (SLI) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

SLI trades at $2.22, down 3.9% in the last 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $48.40 million for 2025, with negative ROE and ROA, though it secured a $225 million DOE grant and is progressing toward a final investment decision for its Arkansas lithium project. Analyst consensus is unanimously bullish with 3 buy ratings.

The outlook hinges on successful project execution and lithium market dynamics, offering growth potential but carrying significant operational and financial risks due to current losses and high cash burn. Investors should weigh the strong analyst support against fundamental weaknesses and project timeline uncertainties.